TRENDING KEYWORDS
Rockwell's (RMTI, $0.39) loss widens in Q4
Rockwell Medical reported Q4 sales of $15.33 million, lower than Q3 sales of $15.99 million. The biopharma company incurred a loss of -$8.94 million, vs. -$7.58 million loss in Q3. It per share loss was $-0.09/share.
In a separate announcement, it was revealed that Rockwell, which is aiming to transform the treatment of iron deficiency and anemia management, has expanded partnership with kidney care provider DaVita Inc. The agreement is intended to bolster Rockwell’s financial ability to supply its partners so they can serve patients undergoing dialysis in their centers.
RMTI's Indicator enters downward trend
The Aroon Indicator for RMTI entered a downward trend on May 26, 2022. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 309 similar instances where the Aroon Indicator formed such a pattern. In 271 of the 309 cases the stock moved lower. This puts the odds of a downward move at 88%.
Current price $1.52 is below $1.78 the lowest support line found by A.I. Throughout the month of 04/26/22 - 05/26/22, the price experienced a -58% Downtrend. During the week of 05/19/22 - 05/26/22, the stock fell -15%.
The 10-day Moving Average for RMTI crossed bearishly below the 50-day moving average on April 25, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RMTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where RMTI advanced for three days, in 186 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
RMTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 82%. During the last month, the daily ratio of advancing to declining volumes was 1 to 2.3.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RMTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. RMTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.627) is normal, around the industry mean (7.994). P/E Ratio (0.000) is within average values for comparable stocks, (54.890). RMTI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.501). RMTI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.021). P/S Ratio (0.207) is also within normal values, averaging (88.486).
The Tickeron SMR rating for this company is 6 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
The average market capitalization across the Pharmaceuticals: Other Industry is 1.8B. The market cap for tickers in the group ranges from 246 to 81.3B. MKKGY holds the highest valuation in this group at 81.3B. The lowest valued company is PEMTF at 246.
The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -0.69%. For the same Industry, the average monthly price growth was -14.33%, and the average quarterly price growth was -28.37%. TNRG experienced the highest price growth at 180%, while EOFBF experienced the biggest fall at -93.93%.
- 3/22/22 5:13 AM: Rockwell Medical (RMTI, $0.38) is a top weekly gainer for penny stocks, rising +15.15%
The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -53.19%. For the same stocks of the Industry, the average monthly volume growth was -69.33% and the average quarterly volume growth was -45.87%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Positive Outlook today, backed by the Volume Indicator. Tickeron has a positive outlook on this group and predicts a further increase by more than 4.00% within the next month with a likelihood of 53%. During the last month, the daily ratio of advancing to declining volumes was 1.45 to 1.
3 stocks in the group of tickers confirmed the positive outlook based on the 15 indicator with average odds of 82%.
The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), Acorda Therapeutics (NASDAQ:ACOR).
The average market capitalization across the group is 2.5B. The market cap for tickers in the group ranges from 5.5M to 10.2B. TEVA holds the highest valuation in this group at 10.2B. The lowest valued company is ACOR at 5.5M.
The average weekly price growth across all stocks in the group was -2.85%. For the same group, the average monthly price growth was -12.94%, and the average quarterly price growth was -15.89%. ALIM experienced the highest price growth at 25.27%, while ACOR experienced the biggest fall at -25.35%.
- 5/24/22 7:00 AM: Teva Pharmaceutical Industries (TEVA, $8.45) was a top weekly gainer, with a +6.83% jump
- 5/21/22 6:30 AM: AcelRx Pharmaceuticals (ACRX, $0.26) is a top weekly gainer for penny stocks, rising +21.49%
- 5/20/22 5:28 AM: China Pharma Holdings (CPHI, $0.25) is a top weekly gainer for penny stocks, rising +15.7%
The average weekly volume growth across all stocks in the group was 307.72%. For the same stocks of the group, the average monthly volume growth was 381.19% and the average quarterly volume growth was 133.63%
- 5/25/22 7:27 AM: The volume for Acorda Therapeutics stock increased for a consecutive 5 days, with an average daily gain of 330%
- 5/20/22 5:22 AM: The volume for AcelRx Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 265% of the 65-Day Volume Moving Average
- 3/31/22 6:34 AM: The volume for AcelRx Pharmaceuticals stock increased for two consecutive days, resulting in a record-breaking daily growth of 317% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Latest blogs by Abhoy Sarkar
Top Blogs
